Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Winning with partnerships

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Nov 25, 2024 8:07am

40 Views

Post# 36328648

RE:RE:RE:RE:RE:Winning with partnerships

And maybe facing another one if they can't get Egrifta manufacturing back up before too long. They could keep a year of inventory in case of problem. It's part of the problem in this company, no accountability.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec